SOURCE: AtCor Medical Holdings Ltd.

July 19, 2007 08:30 ET

Leading International Pharmaceutical Companies Choose AtCor to Assess Central Blood Pressure in Major Clinical Trials

SphygmoCor® System Provides Vital Information About Drug Effects Undetectable Through Traditional Cuff Blood Pressure Monitoring

SYDNEY, AUSTRALIA and LISLE, IL--(Marketwire - July 19, 2007) - AtCor Medical Holdings Limited (ASX: ACG), the developer and marketer of the SphygmoCor® system, which non-invasively measures central blood pressures, today announced that it has signed agreements with three leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States. The total value of the contracts is approximately US $1.8 million.

"These contracts further validate the value of our SphygmoCor® technology for clinical trial applications," said Duncan Ross, AtCor Medical Chief Executive Officer. "The clinical trial market is one of our primary focuses for the SphygmoCor® system and we are delighted to have these pre-eminent companies in our growing customer base."

"New academic research, such as the CAFE and Strong Heart studies, has served to increase awareness of our technology and the importance of noninvasive central blood pressure monitoring, among the pharmaceutical, clinical and research communities," added Ross. "There were over 30 scientific poster sessions incorporating SphygmoCor monitoring presented by scientists from the U.S., Europe and Asia at the 2007 American Society of Hypertension (ASH) Annual Scientific Meeting, and the number of SphygmoCor studies published in international medical journals in the past year has been similarly impressive."

Recently the European Society of Hypertension and the European Society of Cardiology issued guidelines highlighting what major studies have shown: noninvasive central blood pressure assessment reveals important drug effects that cannot be detected by traditional cuff blood pressure measurements. These studies show that elevated central pressure is a superior predictor of cardiovascular events such as heart attacks and strokes. This information is vital in clinical trials and patient care.

Heart disease is the leading cause of death in the U.S. AtCor's SphygmoCor system is the only FDA-cleared, non-invasive method to measure central pressures. Central blood pressure comprises the pressure exerted by the heart's contraction, plus the added pressure, which is reflected back at the heart during that heart-beat. This combined pressure, the pressure the heart pumps against, is increased by arterial stiffening and can be reduced with lifestyle changes and drug therapies.

About AtCor Medical

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,000 SphygmoCor systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

Contact Information